AF
RMD icon

Avanza Fonder’s ResMed RMD Stock Holding History

Avanza Fonder’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50.3K Hold
258
– – ﹤0.01% 451
2026
Q1 		$57.9K Buy
+258
New +$64.3K ﹤0.01% 474

Other funds holding RMD

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
VF
Vest Financial Mclean, Virginia $9.52B AUM 31.6% 1-Year Est. Return
AT
Arbejdsmarkedets Tillaegspension Hilleroed $4.6B AUM
AS
Aware Super Sydney, Australia $7.06B AUM
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
CISOA
Capital Investment Services of America Milwaukee, Wisconsin $1.02B AUM 3.04% 1-Year Est. Return
DJSG
D.J. St. Germain Springfield, Massachusetts $2.78B AUM 23.87% 1-Year Est. Return
MIF
Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
CIM
Confluence Investment Management St. Louis, Missouri $6.4B AUM 9.79% 1-Year Est. Return

Avanza Fonder's RMD Position: Q2 2026 in Review

Avanza Fonder held its ResMed (RMD) position steady in Q2 2026 at 258 shares worth $50.3K. The position accounts for ﹤0.01% of the portfolio, ranked #451.

Avanza Fonder first reported a position in RMD in Q1 2026 and has held it in 2 quarters since. The position peaked at $57.9K in Q1 2026. 257 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

  • Avanza Fonder held 258 shares of ResMed worth $50.3K as of Q2 2026.
  • Avanza Fonder left its ResMed share count unchanged in Q2 2026.
  • ResMed made up ﹤0.01% of Avanza Fonder's portfolio in Q2 2026, its #451 holding.
  • Avanza Fonder first reported a position in ResMed in Q1 2026 and has held it in 2 quarters since.
  • Avanza Fonder's ResMed position peaked at $57.9K in Q1 2026.
  • 257 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on Avanza Fonder's 13F filing for Q2 2026, filed 17 Jul 2026.